Send to:

Choose Destination
See comment in PubMed Commons below
Neurology. 1992 Apr;42(4 Suppl 4):13-26; discussion 41-8.

Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?

Author information

  • 1Department of Neurology, University of South Florida, Tampa 33606.


Selegiline monotherapy has been clearly demonstrated to delay the development of disability in early, otherwise untreated Parkinson's disease patients. It remains uncertain, however, whether this benefit is due to protective effects on residual neurons or to symptomatic effects that mask the detection of underlying disability. This paper examines the evidence and theory supporting the hypotheses that selegiline acts by protective or symptomatic mechanisms and considers what future studies might help clarify these issues.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk